Roland Walter photo
Professor, Division of Hematology
University of Washington
Professor, Clinical Research Division
Fred Hutchinson Cancer Research Center
Adjunct Professor, Department of Laboratory Medicine & Pathology
University of Washington
Adjunct Professor, Department of Epidemiology
University of Washington

Faculty Information


My research is focused on acute myeloid leukemia (AML). I am particularly interested in improving antibody-based therapies, both by optimizing the efficacy/safety profile of existing therapeutics and through the preclinical and early clinical development of novel antigen-directed immunotherapies. As examples of latter efforts, my lab has contributed to candidate drug identification and preclinical development of 5 novel agents that have subsequently advanced to clinical testing (SGN-CD33A, SGN-CD123A, AMG 330, AMV-564, and APVO436). A major area of focus of our research lies in the delineation of the mechanisms of action and resistance that are relevant for antibody-based AML therapeutics and the rational development of combination therapies that can overcome drug resistance. Many of my studies conducted over the last 15+ years have aimed at optimizing CD33-targeted and, more recently, CD123-targeted therapies. In clinical studies, I conduct trials testing novel treatments and innovative care approaches for AML patients. Furthermore, in collaborative research, I use large patient datasets to develop and improve diagnostic and prognostic tools for people with AML.


Education & Training: 
Medical School
University of Zurich
M.D. Faculty of Medicine
University of Zurich
Resident, Internal Medicine
Ratisches Kantons- und Regionalspital
Chur, Switzerland
Resident, Internal Medicine
University Hospital
Zurich, Switzerland
University of Washington
Seattle, WA
Research Fellow, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, WA
Division of Hematology, University of Washington
Seattle, WA
M.S. (Epidemiology, Clinical Research)
University of Washington
Seattle, WA
(206) 667-3599
Mailing Address: 

Fred Hutchinson Cancer Research Center
1100 Fairview Ave. N., D2-190
Seattle, WA 98109-1024

Research & Clinical Interests
Research Interests: 

Acute Myeloid Leukemia; Adoptive Cell Therapy; Antibody; Antigen-Specific Immunotherapy; Bispecific Antibody; CD33; CD123; Clinical Trial; Measurable Residual Disease (MRD); Predictive Modeling; Radioimmunotherapy; Translational Research

Clinical Interests: 

Acute myeloid leukemia; Hematopoietic Cell Transplanation


Walter RB, Raden BW, Kamikura DM, Cooper JA, Bernstein ID. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood. 2005:105(3):1295-1302.

Walter RB, Kantarjian HM, Huang X, Pierce SA, Sun Z, Gundacker HM, Ravandi F, Faderl SH, Tallman MS, Appelbaum FR, Estey EH. The effect of complete remission (CR) and CR with incomplete platelet recovery (CRp) on outcome in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group (ECOG), Southwest Oncology Group (SWOG), and M.D. Anderson Cancer Center study. J Clin Oncol. 2010;28(10):1766-1771.

Walter RB, Gooley TA, Wood BL, Milano F, Fang M, Sorror ML, Estey EH, Salter AI, Lansverk E, Chien JW, Gopal AK, Appelbaum FR, Pagel JM. Impact of pre-transplant minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol. 2011;29(9):1190-1197.

Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, Appelbaum FR, Kantarjian HM, Estey EH. Prediction of early death following induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011;29(33):4417-4424.

Walter RB, Appelbaum FR, Estey EH, Bernstein ID. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood. 2012;119(26):6198-6208.

Walter RB, Buckley SA, Pagel JM, Wood BL, Storer BE, Sandmaier BM, Fang M, Gyurkocza B, Delaney C, Radich JP, Estey EH, Appelbaum FR. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first and second complete remission. Blood. 2013;122(10):1813-1821.

Walter RB, Laszlo GS, Lionberger JM, Pollard JA, Harrington KH, Gudgeon CJ, Othus M, Rafii S, Meshinchi S, Appelbaum FR, Bernstein ID. Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia. Leukemia. 2014;28(10):1969-1977.

Laszlo GS, Gudgeon CJ, Harrington KH, Dell’Aringa J, Newhall KJ, Means GD, Sinclair AM, Kischel R, Frankel SR, Walter RB. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood. 2014;123(4):554-561.

Walter RB, Gyurkocza B, Storer BE, Godwin CD, Pagel JM, Buckley SA, Sorror ML, Wood BL, Storb R, Appelbaum FR, Sandmaier BM. Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. Leukemia. 2015;29(1):137-144.

Walter RB, Othus M, Burnett AK, Löwenberg B, Kantarjian HM, Ossenkoppele GJ, Hills RK, Ravandi F, Pabst T, Evans A, Pierce SR, Vekemans M-C, Appelbaum FR, Estey EH. Resistance prediction in AML: analysis of 4,601 patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center. Leukemia. 2015;29(2):312-320.

Vaughn JE, Othus M, Powell MA, Gardner KM, Rizzuto DL, Hendrie PC, Becker PS, Pottinger PS, Estey EH, Walter RB. Comparative analysis of resource utilization and safety of outpatient management following intensive AML induction/salvage chemotherapy. JAMA Oncol. 2015;1(8):1120-1127.

Zhou Y, Othus M, Araki D, Wood BL, Radich JP, Halpern AB, Mielcarek M, Estey EH, Appelbaum FR, Walter RB. Pre- and post-transplant quantification of measurable (“minimal”) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. Leukemia. 2016;30(7):1456-1464.

Reusch U, Harrington KH, Gudgeon CH, Fucek I, Ellwanger K, Weichel M, Knackmuss S, Zhukovsky E, Fox JA, Kunkel LA, Guenot J, Walter RB. Characterization of CD33/CD3 tetravalent bispecific tandem diabodies (TandAbs) for the treatment of acute myeloid leukemia. Clin Cancer Res. 2016;22(23):5829-5838.

Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou, Y, Mielcarek M, Estey EH, Appelbaum FR, Walter RB. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: is it time to move toward a minimal residual disease-based definition of complete remission? J Clin Oncol. 2016;34(4):329-336.

Correnti CE, Laszlo GS, de van der Schueren WJ, Godwin CD, Bandaranayake A, Busch MA, Gudgeon CJ, Bates OM, Olson JM, Mehlin C, Walter RB. Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation. Leukemia. 2018;32(5):1239-1243.

Humbert O, Laszlo GS, Sichel S, Ironside C, Haworth KG, Bates OM, Beddoe ME, Carrillo RR, Kiem H-P, Walter RB. Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2. Leukemia. 2019;33(3):762-766.

Klupsch K, Baeriswyl, V, Scholz R, Dannenberg J, Santimaria R, Senn D, Kage E, Zumsteg A, Attinger-Toller I, von der Bey U, König-Friedrich S, Dupuy F, Lembke W, Albani C, Wendelspiess S, Dinkel L, Saro D, Hepler RW, Laszlo GS, Gudgeon CJ, Bertschinger J, Brack S, Walter RB. COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia. Leukemia. 2019;33(3):805-808.

Palmieri R, Othus M, Halpern AB, Percival MEM, Godwin CD, Becker PS, Walter RB. Accuracy of SIE/SIES/GITMO consensus criteria for unfitness to predict early mortality after intensive chemotherapy in adults with AML or other high-grade myeloid neoplasm. J Clin Oncol. 2020;38(35): 4163-4174.

Godwin CD, Laszlo GS, Fiorenza S, Garling EE, Phi TD, Bates OM, Correnti CE, Hoffstrom BG, Lunn MC, Humbert O, Kiem HP, Turtle CJ, Walter RB. Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy. Leukemia. 2021; in press.